Cancer Research and Treatment

Original Articles

Genitourinary cancer

Optimal Definition of Biochemical Recurrence in Patients Who Receive Salvage Radiotherapy Following Radical Prostatectomy for Prostate Cancer: Sung Uk Lee, Jae-Sung Kim, Young Seok Kim, Jaeho Cho, Seo Hee Choi, Taek-Keun Nam, Song Mi Jeong, Youngkyong Kim, Youngmin Choi, Dong Eun Lee, Won Park, Kwan Ho Cho; Cancer Res Treat. 2022;54(4):1191-1199. Published online December 7, 2021; DOI: https://doi.org/10.4143/crt.2021.985

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study proposed the optimal definition of biochemical recurrence (BCR) after salvage radiotherapy (SRT) following radical prostatectomy for prostate cancer.
Materials and Methods
Among 1,117 patients who had received SRT, data from 205 hormone-naïve patients who experienced post-SRT prostate-specific antigen (PSA) elevation were included in a multi-institutional database. The primary endpoint was to determine the PSA parameters predictive of distant metastasis (DM). Absolute serum PSA levels and the prostate-specific antigen doubling time (PSA-DT) were adopted as PSA parameters.
Results
When BCR was defined based on serum PSA levels ranging from 0.4 ng/mL to nadir+2.0 ng/mL, the 5-year probability of DM was 27.6%-33.7%. The difference in the 5-year probability of DM became significant when BCR was defined as a serum PSA level of 0.8 ng/ml or higher (1.0-2.0 ng/mL). Application of a serum PSA level of ≥ 0.8 ng/mL yielded a c-index value of 0.589. When BCR was defined based on the PSA-DT, the 5-year probability was 22.7%-39.4%. The difference was significant when BCR was defined as a PSA-DT ≤ 3 months and ≤ 6 months. Application of a PSA-DT ≤ 6 months yielded the highest c-index (0.660). These two parameters complemented each other; for patients meeting both PSA parameters, the probability of DM was 39.5%-44.5%; for those not meeting either parameter, the probability was 0.0%-3.1%.
Conclusion
A serum PSA level > 0.8 ng/mL was a reasonable threshold for the definition of BCR after SRT. In addition, a PSA-DT ≤ 6 months was significantly predictive of subsequent DM, and combined application of both parameters enhanced predictability.

Citations

Citations to this article as recorded by

New Prostate MRI Scoring Systems (PI-QUAL, PRECISE, PI-RR, and PI-FAB): AJR Expert Panel Narrative Review
Adriano Basso Dias, Silvia D. Chang, Fiona M. Fennessy, Soleen Ghafoor, Sangeet Ghai, Valeria Panebianco, Andrei S. Purysko, Francesco Giganti
American Journal of Roentgenology.2024;[Epub] CrossRef
A Prospective Randomized Multicenter Study on the Impact of [18F]F-Choline PET/CT Versus Conventional Imaging for Staging Intermediate- to High-Risk Prostate Cancer
Laura Evangelista, Fabio Zattoni, Marta Burei, Daniele Bertin, Eugenio Borsatti, Tanja Baresic, Mohsen Farsad, Emanuela Trenti, Mirco Bartolomei, Stefano Panareo, Luca Urso, Giuseppe Trifirò, Elisabetta Brugola, Franca Chierichetti, Davide Donner, Lucia S
Journal of Nuclear Medicine.2024; 65(7): 1013. CrossRef
Comparison of the Effects of DOTA and NOTA Chelators on 64Cu-Cudotadipep and 64Cu-Cunotadipep for Prostate Cancer
Inki Lee, Min Hwan Kim, Kyongkyu Lee, Keumrok Oh, Hyunwoo Lim, Jae Hun Ahn, Yong Jin Lee, Gi Jeong Cheon, Dae Yoon Chi, Sang Moo Lim
Diagnostics.2023; 13(16): 2649. CrossRef

6,428 View
178 Download
2 Web of Science
3 Crossref

Clinical Outcomes of Postoperative Radiotherapy Following Radical Prostatectomy in Patients with Localized Prostate Cancer: A Multicenter Retrospective Study (KROG 18-01) of a Korean Population: Sung Uk Lee, Kwan Ho Cho, Won Park, Won Kyung Cho, Jae-Sung Kim, Chan Woo Wee, Young Seok Kim, Jin Ho Kim, Taek-Keun Nam, Jaeho Cho, Song Mi Jeong, Youngkyong Kim, Su Jung Shim, Youngmin Choi, Jun-Sang Kim; Cancer Res Treat. 2020;52(1):167-180. Published online June 25, 2019; DOI: https://doi.org/10.4143/crt.2019.126

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to investigate the clinical outcomes of postoperative radiotherapy (PORT) patients who underwent radical prostatectomy for localized prostate cancer.
Materials and Methods
Localized prostate cancer patients who received PORT after radical prostatectomy between 2001 and 2012 were identified retrospectively in a multi-institutional database. In total, 1,117 patients in 19 institutions were included. Biochemical failure after PORT was defined as prostate-specific antigen (PSA) ≥ nadir+2 after PORT or initiation of androgen deprivation therapy (ADT) for increasing PSA regardless of its value.
Results
Ten-year biochemical failure-free survival, clinical failure-free survival, distant metastasisfree survival, overall survival (OS), and cause-specific survival were 60.5%, 76.2%, 84.4%, 91.1%, and 96.6%, respectively, at a median of 84 months after PORT. Pre-PORT PSA ≤ 0.5 ng/ml and Gleason’s score ≤ 7 predicted favorable clinical outcomes, with 10-year OS rates of 92.5% and 94.1%, respectively. The 10-year OS rate was 82.7% for patients with a PSA > 1.0 ng/mL and 86.0% for patients with a Gleason score of 8-10. The addition of longterm ADT (≥ 12 months) to PORT improved OS, particularly in those with a Gleason score of 8-10 or ≥ T3b.
Conclusion
Clinical outcomes of PORT in a Korean prostate cancer population were very similar to those in Western countries. Lower Gleason score and serum PSA level at the time of PORT were significantly associated with favorable outcomes. Addition of long-term ADT (≥ 12 months) to PORT should be considered, particularly in unfavorable risk patients with Gleason scores of 8-10 or ≥ T3b.

Citations

Citations to this article as recorded by

Optimal Definition of Biochemical Recurrence in Patients Who Receive Salvage Radiotherapy Following Radical Prostatectomy for Prostate Cancer
Sung Uk Lee, Jae-Sung Kim, Young Seok Kim, Jaeho Cho, Seo Hee Choi, Taek-Keun Nam, Song Mi Jeong, Youngkyong Kim, Youngmin Choi, Dong Eun Lee, Won Park, Kwan Ho Cho
Cancer Research and Treatment.2022; 54(4): 1191. CrossRef
A discussion on controversies and ethical dilemmas in prostate cancer screening
Satish Chandra Mishra
Journal of Medical Ethics.2021; 47(3): 152. CrossRef
Clinical Outcome of Salvage Radiotherapy for Locoregional Clinical Recurrence After Radical Prostatectomy
Sung Uk Lee, Kwan Ho Cho, Jin Ho Kim, Young Seok Kim, Taek-Keun Nam, Jae-Sung Kim, Jaeho Cho, Seo Hee Choi, Su Jung Shim, Jin Hee Kim, Ah Ram Chang
Technology in Cancer Research & Treatment.2021;[Epub] CrossRef

7,883 View
209 Download
3 Web of Science
3 Crossref

The Effect of Hospital Case Volume on Clinical Outcomes in Patients with Nasopharyngeal Carcinoma: A Multi-institutional Retrospective Analysis (KROG-1106): Boram Ha, Kwan Ho Cho, Sung Ho Moon, Chang-Geol Lee, Ki Chang Keum, Yeon-Sil Kim, Hong-Gyun Wu, Jin Ho Kim, Yong Chan Ahn, Dongryul Oh, Jae Myoung Noh, Jong Hoon Lee, Sung Hwan Kim, Won Taek Kim, Young-Taek Oh, Min Kyu Kang, Jin Hee Kim, Ji-Yoon Kim, Moon-June Cho, Chul Seoung Kay, Jin Hwa Choi; Cancer Res Treat. 2019;51(1):12-23. Published online February 5, 2018; DOI: https://doi.org/10.4143/crt.2017.273

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to investigate the effect of hospital case volume on clinical outcomes in patients with nasopharyngeal carcinoma (NPC).
Materials and Methods
Data on 1,073 patients with cT1-4N0-3M0 NPC were collected from a multi-institutional retrospective database (KROG 11-06). All patients received definitive radiotherapy (RT) either with three-dimensional-conformal RT (3D-CRT) (n=576) or intensity-modulated RT (IMRT) (n=497). The patients were divided into two groups treated at high volume institution (HVI) (n=750) and low volume institution (LVI) (n=323), defined as patient volume ≥ 10 (median, 13; range, 10 to 18) and < 10 patients per year (median, 3; range, 2 to 6), respectively. Endpoints were overall survival (OS) and loco-regional progression-free survival (LRPFS).
Results
At a median follow-up of 56.7 months, the outcomes were significantly better in those treated at HVI than at LVI. For the 614 patients of propensity score-matched cohort, 5-year OS and LRPFS were consistently higher in the HVI group than in the LVI group (OS: 78.4% vs. 62.7%, p < 0.001; LRPFS: 86.2% vs. 65.8%, p < 0.001, respectively). According to RT modality, significant difference in 5-year OS was observed in patients receiving 3D-CRT (78.7% for HVI vs. 58.9% for LVI, p < 0.001) and not in those receiving IMRT (77.3% for HVI vs. 75.5% for LVI, p=0.170).
Conclusion
A significant relationship was observed between HVI and LVI for the clinical outcomes of patients with NPC. However, the difference in outcome becomes insignificant in the IMRT era, probably due to the standardization of practice by education.

Citations

Citations to this article as recorded by

Accumulated Dose Deviation of Rotational and Residual Setup Errors on Nasopharyngeal Carcinoma Using MIM Treated by Helical Tomotherapy
Wenyan Yao, Jiang Hu, Peixun Xu, Mengxue He, Yongwen Fang, Mingzhi Liu, Zongtai Li, Huilang He, Hui Liu, Wenzhao Sun, Senkui Xu
Technology in Cancer Research & Treatment.2023;[Epub] CrossRef
Systematic Review and Meta-analysis of the Association Between Radiation Therapy Treatment Volume and Patient Outcomes
Jerry Ye Aung Kyaw, Alice Rendall, Erin F. Gillespie, Tom Roques, Laurence Court, Yolande Lievens, Alison C. Tree, Chris Frampton, Ajay Aggarwal
International Journal of Radiation Oncology*Biology*Physics.2023; 117(5): 1063. CrossRef
The Influence of Hospital Volume on the Outcomes of Nasopharyngeal, Sinonasal, and Skull-Base Tumors: A Systematic Review of the Literature
Stephanie Flukes, Rahul K. Sharma, Shivangi Lohia, Marc A. Cohen
Journal of Neurological Surgery Part B: Skull Base.2022; 83(03): 270. CrossRef
A Comprehensive Analysis of Treatment Management and Survival Outcomes in Nasopharyngeal Carcinoma
Khodayar Goshtasbi, Brandon M. Lehrich, Jack L. Birkenbeuel, Arash Abiri, Jeremy P. Harris, Edward C. Kuan
Otolaryngology–Head and Neck Surgery.2021; 165(1): 93. CrossRef
Hospital volume and physician volume in association with survival in patients with nasopharyngeal cancer after radiation therapy
Tzu-Yu Lai, Chiu-Mei Yeh, Yu-Wen Hu, Chia-Jen Liu
Radiotherapy and Oncology.2020; 151: 190. CrossRef

10,123 View
215 Download
5 Web of Science
5 Crossref

Clinical Outcomes of Proton Beam Therapy for Choroidal Melanoma at a Single Institute in Korea: Tae Wan Kim, Euncheol Choi, Jeonghoon Park, Dong-ho Shin, Su Kyung Jung, Susie Seok, Kwan Ho Cho, Joo-Young Kim, Dae Yong Kim, Tae Hyun Kim, Yang Kwon Suh, Yeon Joo Kim, Sung Ho Moon; Cancer Res Treat. 2018;50(2):335-344. Published online April 19, 2017; DOI: https://doi.org/10.4143/crt.2017.070

Abstract PDF PubReader ePub

Purpose
This study retrospectively evaluated the clinical outcomes and complications of proton beam therapy (PBT) in a single institution in Korea and quantitatively analyzed the change in tumor volume after PBT using magnetic resonance imaging (MRI).
Materials and Methods
Twenty-four treatment-naïve patients who underwent PBT for choroidal melanoma between 2009 and 2015 were reviewed. Dose fractionation was 60-70 cobalt gray equivalents over 5 fractions. Orbital MRIs were taken at baseline and 3, 6, and 12 months after PBT and annually thereafter. The tumor volume was reconstructed and evaluated by stacking the tumor boundary in each thin-sliced axial T1-weighted image using MIM software.
Results
The median follow-up duration was 36.5 months (range, 9 to 82 months). One patient had suspicious local progression and two patients had distant metastasis. The 3-year local progression-free survival, distant metastasis-free survival, and overall survival rates were 95.8%, 95.8%, and 100%,respectively. Five Common Terminology Criteria for Adverse Event ver. 4.03 grade 3-4 toxicities were observed in four patients (16.7%), including one with neovascular glaucoma. The mean tumor volume at the baseline MRI was 0.565±0.084 mL (range, 0.074 to 1.610 mL), and the ratios of the mean volume at 3, 6, and 12 months to that at baseline were 81.8%, 67.3%, and 60.4%, respectively.
Conclusion
The local controlrate and complication profile after PBT in patientswith choroidal melanoma in Korea were comparable with those reported in a previous PBT series. The change in tumor volume after PBT exhibited a gradual regression pattern on MRI.

Citations

Citations to this article as recorded by

Efficacy and safety of proton radiotherapy in treating choroidal melanoma: a systematic review and meta-analysis
Yuxin Miao, Tingwei Zheng, Qiuning Zhang, Meixuan Li, Qihang Lei, Qin Liu, Hongtao Luo, Huiling Bai
Radiation Oncology.2025;[Epub] CrossRef
Opportunities and challenges of upright patient positioning in radiotherapy
Lennart Volz, James Korte, Maria Chiara Martire, Ye Zhang, Nicholas Hardcastle, Marco Durante, Tomas Kron, Christian Graeff
Physics in Medicine & Biology.2024; 69(18): 18TR02. CrossRef
Magnetic Resonance Imaging in the Clinical Care for Uveal Melanoma Patients—A Systematic Review from an Ophthalmic Perspective
Myriam G. Jaarsma-Coes, Lisa Klaassen, Marina Marinkovic, Gregorius P. M. Luyten, T. H. Khanh Vu, Teresa A. Ferreira, Jan-Willem M. Beenakker
Cancers.2023; 15(11): 2995. CrossRef
When Is the Optimum Radiological Response to Proton Beam Therapy in Uveal Melanoma?
Matthew Gillam, Glenn Ace Fenech, Oliver Chadwick, Jonathan Nairn, Vikas Chadha, Julie Connolly, Oliver Cram, Wilma Kincaid, Paul Cauchi
Ocular Oncology and Pathology.2023; 9(5-6): 130. CrossRef
Optimization of proton therapy eye-treatment systems toward improved clinical performances
Eustache Gnacadja, Cédric Hernalsteens, Stewart Boogert, Quentin Flandroy, Carolina Fuentes, Laurence J. Nevay, Nicolas Pauly, Eliott Ramoisiaux, William Shields, Robin Tesse, Raphael Van Roermund, Marion Vanwelde
Physical Review Research.2022;[Epub] CrossRef
Who Will Benefit from Charged-Particle Therapy?
Kyung Su Kim, Hong-Gyun Wu
Cancer Research and Treatment.2021; 53(3): 621. CrossRef
Uveal Melanoma: A Review of the Literature and Personal Experiences
Yong Joon Kim, Christopher Seungkyu Lee, Sung Chul Lee
Journal of Retina.2021; 6(2): 65. CrossRef
Carbon Fiducial Markers for Tumor Localization in Stereotactic Irradiation of Uveal Melanoma
Timothy T. Xu, Jose S. Pulido, Ian F. Parney, Cristiane M. Ida, Lauren A. Dalvin, Timothy W. Olsen
Ocular Oncology and Pathology.2021; 7(5): 368. CrossRef
Uveal Melanoma in Asians: A Review
Pradeep Manchegowda, Arun D. Singh, Carol Shields, Swathi Kaliki, Parag Shah, Lingam Gopal, Pukhraj Rishi
Ocular Oncology and Pathology.2021; 7(3): 159. CrossRef
Preliminary Dosimetric Study of Proton Minibeam Radiation Therapy for the Treatment of Choroidal Melanoma
Myeongsoo Kim, Sang Soo Kim, Haksoo Kim, Sung Ho Moon, Young Kyung Lim, Ui-Jung Hwang, Sang Hyoun Choi
Journal of the Korean Physical Society.2020; 77(5): 447. CrossRef
Visual outcomes of proton beam therapy for choroidal melanoma at a single institute in the Republic of Korea
Su-Kyung Jung, Young-Hoon Park, Dong-ho Shin, Hak-Soo Kim, Jong-Hwi Jung, Tae-Hyun Kim, Sung Ho Moon, Vikas Khetan
PLOS ONE.2020; 15(12): e0242966. CrossRef

11,861 View
271 Download
11 Web of Science
11 Crossref

Comparison of the Clinical Outcomes of Patients with Squamous Cell Carcinoma of the Tonsil Receiving Postoperative Ipsilateral Versus Bilateral Neck Radiotherapy: A Propensity Score Matching Analysis (KROG 11-07): Youngkyong Kim, Kwan Ho Cho, Sung Ho Moon, Chang Geol Lee, Ki Chang Keum, Sang-wook Lee, Yong Chan Ahn, Dongryul Oh, Yeon-Sil Kim, Yong Kyun Won, Hong-Gyun Wu, J. Hun Hah, Young-Taek Oh; Cancer Res Treat. 2017;49(4):1097-1105. Published online February 9, 2017; DOI: https://doi.org/10.4143/crt.2016.425

Abstract PDF PubReader ePub

Purpose
The impact of postoperative ipsilateral neck radiotherapy (INRT) versus bilateral neck radiotherapy (BNRT) on the clinical outcomes of patients with tonsillar squamous cell carcinoma was analyzed retrospectively.
Materials and Methods
Between October 2001 and June 2012, 241 patients with T1-2 and N0-N2b tonsillar carcinoma from 16 institutes underwent postoperative INRT (n=84) or BNRT (n=157) following a tonsillectomy. Seventy patientswere identified from each group by propensity score matching and compared in terms of the overall survival (OS), disease-free survival (DFS), locoregional relapse-free survival (LRRFS), and distant metastasis-free survival (DMFS) rates calculated using the Kaplan-Meier method with a log-rank test.
Results
The median follow-up was 55 months (range, 3 to 133 months). The survival outcomes in the INRT and BNRT groupswere similar: 5-year OS (92.8% vs. 94.0%, p=0.985), DFS (80.5% vs. 94.2%. p=0.085), LRRFS (88.1% vs. 97.1%, p=0.083), and DMFS (92.7% vs. 97.0%, p=0.370). Subgroup analysis revealed no contralateral neck recurrence in 61 patients with T1-2N0-2a regardless of the treatment groups. For 79 patients with N2b, contralateral neck recurrence was more common in the INRT group than in the BNRT group (7.9% vs. 0.0%), but the difference was not significant (p=0.107). The overall grade ≥ 2 toxicities were lower in the INRT group: acute (45.7% vs. 74.3%, p=0.001) and late (4.3% vs. 31.4%, p < 0.001), respectively.
Conclusion
INRT is an attractive strategy for patients with T1-2N0-2a tonsillar carcinoma compared to BNRT. For patients with N2b, there was a small risk of contralateral neck recurrence when treated with INRT, but its impact on the OS was limited with successful salvage treatment.

Citations

Citations to this article as recorded by

A multi‐institutional feasibility lead‐in trial of lymphatic mapping with SPECT–CT for evaluating contralateral disease in lateralized oropharynx cancer using 99m‐technetium sulfur colloid
Leba Michael Sarkis, Christopher MKL Yao, Aaron Hendler, Ravi Mohan, Michael Au, Han Zhang, Antoine Eskander, Kevin Higgins, Danielle MacNeil, Sharon Tzelnick, David Goldstein, Ali Hosni, John R. de Almeida
Head & Neck.2024; 46(12): 3038. CrossRef
Radiation Therapy for HPV-Positive Oropharyngeal Squamous Cell Carcinoma: An ASTRO Clinical Practice Guideline
Danielle N. Margalit, Christopher J. Anker, Michalis Aristophanous, Musaddiq Awan, Gopal K. Bajaj, Lisa Bradfield, Joseph Califano, Jimmy J. Caudell, Christina H. Chapman, Adam S. Garden, Paul M. Harari, Amanda Helms, Alexander Lin, Ellie Maghami, Ranee M
Practical Radiation Oncology.2024; 14(5): 398. CrossRef
Proton pencil beam scanning radiotherapy in the postoperative treatment of p16 positive squamous cell tonsillar cancer – evaluation of toxicity and effectivity
Jiří Kubeš, Sarah Al-Hamami, Silvia Sláviková, Pavel Vítek, Alexandra Haas, Kateřina Dědečková, Barbora Ondrová, Michal Andrlik, Matěj Navrátil, Eliška Rotnáglová, Vladimír Vondráček
European Archives of Oto-Rhino-Laryngology.2024; 281(10): 5447. CrossRef
Unilateral radiotherapy for tonsillar cancer with multiple ipsilateral neck lymph nodes
Tae Hyun Kim, Hong-Gyun Wu, Soon-Hyun Ahn, Woo-Jin Jeong, Wonjae Cha, Keun-Yong Eom
Radiation Oncology Journal.2024; 42(3): 192. CrossRef
Impact of Postoperative Neck Radiotherapy Volumes on Long‐Term Unstimulated Saliva Flow Following Primary Surgery and Ipsilateral Neck Dissection for Oral Cavity Squamous Cell Carcinoma
Claire M. Rooney, Shao Hui Huang, Jie Su, Scott Bratman, John Cho, John de Almeida, Michael Glogauer, David Goldstein, Ezra Hahn, Ali Hosni, Andrew Hope, Jonathan Irish, John Kim, Brian O'Sullivan, Jolie Ringash, Anna Spreafico, Jillian Tsai, John Waldron
Head & Neck.2024;[Epub] CrossRef
Association of Unilateral Radiotherapy With Contralateral Lymph Node Failure Among Patients With Squamous Cell Carcinoma of the Tonsil
Niema B. Razavian, Ralph B. D’Agostino, Cole R. Steber, Corbin A. Helis, Ryan T. Hughes
JAMA Network Open.2023; 6(2): e2255209. CrossRef
Low contralateral neck recurrence risk with ipsilateral neck radiotherapy in N2b tonsillar squamous cell carcinoma
Divya Natesan, Christina K. Cramer, Taofik Oyekunle, Donna Niedzwiecki, David M. Brizel, Yvonne M. Mowery
Oral Oncology.2023; 139: 106362. CrossRef
Characterizing Lymph Node Burden With Elective Unilateral Neck Irradiation in Human Papillomavirus-Positive Tonsil Squamous Cell Carcinoma: Defining the Upper Limits
Jared H Hara, Stanley I Gutiontov, Sophia Uddin, Ari J Rosenberg, Alexander T Pearson, Zhen Gooi, Elizabeth A Blair, Nishant Agrawal, Everett E Vokes, Daniel T Ginat, Daniel J Haraf, Aditya Juloori
Cureus.2022;[Epub] CrossRef
Evaluating contralateral neck failure in patients with lateralized OPSCC treated with transoral robotic surgery and neck management based on pre-operative SPECT-CT lymphatic mapping
Ilyes Berania, Ali Hosni, Carissa M. Thomas, David Goldstein, Andrew Bayley, Ravi Mohan, Aaron Hendler, Richard M. Cooper, John R. de Almeida
Journal of Otolaryngology - Head & Neck Surgery.2022;[Epub] CrossRef
Short‐term and long‐term unstimulated saliva flow following unilateral vs bilateral radiotherapy for oropharyngeal carcinoma
Shao Hui Huang, John R. de Almeida, Erin Watson, Michael Glogauer, Wei Xu, Sareh Keshavarzi, Brian O'Sullivan, Jolie Ringash, Andrew Hope, Andrew Bayley, Scott V. Bratman, John Cho, Meredith Giuliani, John Kim, John Waldron, Anna Spreafico, David P Goldst
Head & Neck.2021; 43(2): 456. CrossRef
Ipsilateral radiation for squamous cell carcinoma of the tonsil: American Radium Society appropriate use criteria executive summary
C. Jillian Tsai, Thomas J. Galloway, Danielle N. Margalit, Richard L. Bakst, Beth M. Beadle, Jonathan J. Beitler, Steven Chang, Allen Chen, Jay Cooper, Shlomo A. Koyfman, John A. Ridge, Jared Robbins, Minh Tam Truong, Sue S. Yom, Farzan Siddiqui
Head & Neck.2021; 43(1): 392. CrossRef
Healthcare resource utilization following unilateral versus bilateral radiation therapy for oropharyngeal carcinoma
Ali Hosni, Shao Hui Huang, Wei Xu, Jie Su, Erin Watson, Michael Glogauer, Andrew Bayley, Scott V. Bratman, John Cho, Meredith Giuliani, Andrew Hope, John Kim, Brian O'Sullivan, Jolie Ringash, Anna Spreafico, David P. Goldstein, John Waldron, John R. de Al
Radiotherapy and Oncology.2021; 156: 95. CrossRef
Refining Guidelines Regarding Unilateral Treatment in Patients With Well-lateralized Squamous Cell Carcinoma of the Palatine Tonsil and Multiple Positive Nodes or Extranodal Extension
Robert J. Amdur, Paul M. Harari, Peter T. Dziegielewski, William M. Mendenhall
Practical Radiation Oncology.2021; 11(3): e247. CrossRef
Unilateral versus bilateral nodal irradiation: Current evidence in the treatment of squamous cell carcinoma of the head and neck
Sandra Nuyts, Heleen Bollen, Avrahram Eisbruch, June Corry, Primoz Strojan, Antti A. Mäkitie, Johannes A. Langendijk, William M. Mendenhall, Robert Smee, Remco DeBree, Anne W. M. Lee, Alessandra Rinaldo, Alfio Ferlito
Head & Neck.2021; 43(9): 2807. CrossRef
The treatment of tonsillar squamous cell carcinoma at Hue Central Hospital
Phuong Nam Tran
Journal of Clinical Medicine- Hue Central Hospital.2021;[Epub] CrossRef
Efficacy of Postoperative Unilateral Neck Irradiation in Patients with Buccal Mucosa Squamous Carcinoma with Extranodal Extension: A Propensity Score Analysis
Chia-Hsin Lin, Chien-Yu Lin, Kang-Hsing Fan, Sheng-Ping Hung, Yung-Chih Chou, Chia-Jen Liu, Wen-Chi Chou, Yen-Chao Chen, Shiang-Fu Huang, Chung-Jan Kang, Kai-Ping Chang, Hung-Ming Wang, Ann-Joy Cheng, Joseph Tung-Chieh Chang
Cancers.2021; 13(23): 5997. CrossRef
Contralateral nodal failures in oropharyngeal cancers after TORS and unilateral neck management: A retrospective study
Axel Sahovaler, John J. W. Lee, Wei Xu, Susie Su, Ali Hosni, Andrew Bayley, David P. Goldstein, John R. de Almeida
Journal of Otolaryngology - Head & Neck Surgery.2021;[Epub] CrossRef
Lymphatic mapping with SPECT‐CT for evaluation of contralateral drainage in lateralized oropharyngeal cancers using an awake injection technique
Carissa M. Thomas, Mohemmed N. Khan, Ravi Mohan, Aaron Hendler, Ali Hosni, Douglas B. Chepeha, David P. Goldstein, Richard M Cooper, John R. de Almeida
Head & Neck.2020; 42(3): 385. CrossRef
Pretreatment predictive factors for feasibility of oral intake in adjuvant concurrent chemoradiotherapy for patients with locally advanced squamous cell carcinoma of the head and neck
Hidenori Kimura, Satoshi Hamauchi, Sadayuki Kawai, Yusuke Onozawa, Hirofumi Yasui, Aiko Yamashita, Hirofumi Ogawa, Tsuyoshi Onoe, Tomoyuki Kamijo, Yoshiyuki Iida, Tetsuro Onitsuka, Tomoya Yokota
International Journal of Clinical Oncology.2020; 25(2): 258. CrossRef
Désescalade thérapeutique dans les cancers de l’oropharynx induit par les HPV : mise au point
C. Lahmamssi, J.-B. Guy, N. Benchekroun, Z. Bouchbika, N. Taoufik, H. Jouhadi, S. Sahraoui, A. Benider, M. Ben Mrad, O. Jmour, A. Bousarsar, M.L. Lan, Q. Lei, M. Benna, D. Moslemi, A. Vallard, N. Magné
Cancer/Radiothérapie.2020; 24(3): 258. CrossRef
The impact of tongue-deviating and tongue-depressing oral stents on long-term radiation-associated symptoms in oropharyngeal cancer survivors
Sonja Stieb, Ismael Perez-Martinez, Abdallah S.R. Mohamed, Stockton Rock, Nimit Bajaj, Tanaya S. Deshpande, Mohamed Zaid, Adam S. Garden, Ryan P. Goepfert, Richard Cardoso, Renata Ferrarotto, Jay P. Reddy, Jack Phan, William H. Morrison, David I. Rosentha
Clinical and Translational Radiation Oncology.2020; 24: 71. CrossRef
Is there a patient population with squamous cell carcinoma of the head and neck region who might benefit from de-intensification of postoperative radiotherapy?
Yonca Onbasi, Sebastian Lettmaier, Markus Hecht, Sabine Semrau, Heinrich Iro, Marco Kesting, Rainer Fietkau, Marlen Haderlein
Strahlentherapie und Onkologie.2019; 195(6): 482. CrossRef
Selection of lymph node target volumes for definitive head and neck radiation therapy: a 2019 Update
Julian Biau, Michel Lapeyre, Idriss Troussier, Wilfried Budach, Jordi Giralt, Cai Grau, Joanna Kazmierska, Johannes A. Langendijk, Mahmut Ozsahin, Brian O'Sullivan, Jean Bourhis, Vincent Grégoire
Radiotherapy and Oncology.2019; 134: 1. CrossRef
Risk of post-operative, pre-radiotherapy contralateral neck recurrence in patients treated with surgery followed by adjuvant radiotherapy for human papilloma virus-associated tonsil cancer
Jared Gershowitz, Hann-Hsiang Chao, Abigail Doucette, John N Lukens, Samuel Swisher-McClure, Gregory S Weinstein, Bert W O’Malley Jr, Ara A Chalian, Christopher H Rassekh, Jason G Newman, Roger B Cohen, Joshua M Bauml, Charu Aggarwal, Alexander Lin
The British Journal of Radiology.2019;[Epub] CrossRef

9,984 View
315 Download
23 Web of Science
24 Crossref

Identification of Prognostic Risk Factors for Transient and Persistent Lymphedema after Multimodal Treatment for Breast Cancer: Myungsoo Kim, Kyung Hwan Shin, So-Youn Jung, Seeyoun Lee, Han-Sung Kang, Eun Sook Lee, Seung Hyun Chung, Yeon-Joo Kim, Tae Hyun Kim, Kwan Ho Cho; Cancer Res Treat. 2016;48(4):1330-1337. Published online February 3, 2016; DOI: https://doi.org/10.4143/crt.2015.463

Abstract PDF PubReader ePub

Purpose
The purpose of this study is to identify risk factors for transient lymphedema (TLE) and persistent lymphedema (PLE) following treatment for breast cancer. Materials and Methods A total of 1,073 patients who underwent curative breast surgery were analyzed. TLE was defined as one episode of arm swelling that had resolved spontaneously by the next followup; arm swelling that persisted over two consecutive examinations was considered PLE.
Results
At a median follow-up period of 5.1 years, 370 cases of lymphedema were reported, including 120 TLE (11.2%) and 250 PLE (23.3%). Initial grade 1 swelling was observed in 351 patients, of which 120 were limited to TLE (34%), while the other 231 progressed to PLE (66%). All initial swelling observed in TLE patients was classified as grade 1. In multivariate analysis, chemotherapy with taxane and supraclavicular radiation therapy (SCRT) were associated with development of TLE, whereas SCRT, stage III cancer and chemotherapy with taxane were identified as risk factors for PLE (p < 0.05). The estimated incidence of TLE among initial grade 1 patients was calculated using up to three treatment-related risk factors (number of dissected axillary lymph nodes, SCRT, and taxane chemotherapy). The approximate ratios of TLE and PLE based on the number of risk factors were 7:1 (no factor), 1:1 (one factor), 1:2 (two factors), and 1:3 (three factors). Conclusion One-third of initial swelling events were transient, whereas the other two-thirds of patients experienced PLE. Estimation of TLE and PLE based on known treatment factors could facilitate prediction of this life-long complication.

Citations

Citations to this article as recorded by

Efficacy of preoperative lymphoscintigraphy in predicting surgical outcomes of lymphaticovenous anastomosis in lower extremity lymphedema: Clinical correlations in gynecological cancer-related lymphedema
Min Young Yoo, Kyong-Je Woo, Seo Young Kang, Byung Seok Moon, Bom Sahn Kim, Hai-Jeon Yoon, Andrea Giannini
PLOS ONE.2024; 19(1): e0296466. CrossRef
Lymphatic remapping by long-term lymphoscintigraphy follow-up in secondary lymphedema after breast cancer surgery
Garam Hong, Koeun Lee, Sangwon Han, Jae Yong Jeon
Scientific Reports.2024;[Epub] CrossRef
The effect of exercise and educational programs for breast cancer patients on the development of breast cancer-related lymphoedema: secondary endpoint from a randomized controlled trial in the Setouchi Breast Project-10
Shogo Nakamoto, Takayuki Iwamoto, Naruto Taira, Yukiko Kajiwara, Kengo Kawada, Daisuke Takabatake, Yuichiro Miyoshi, Shinichiro Kubo, Yoko Suzuki, Mari Yamamoto, Yutaka Ogasawara, Minami Hatono, Seiji Yoshitomi, Kyoko Hara, Asako Sasahara, Shozo Ohsumi, M
Breast Cancer.2024; 31(5): 969. CrossRef
Taxanes and Breast Cancer‐Related Lymphedema
Daniel Najafali, Charalampos Siotos, George Kokosis
Journal of Surgical Oncology.2024;[Epub] CrossRef
A Single Institution Experience With Immediate Lymphatic Reconstruction: Impact of Insurance Coverage on Risk Reduction
Anne Huang, Emma Koesters, Rebecca M. Garza, Summer E. Hanson, David W. Chang
Journal of Surgical Oncology.2024;[Epub] CrossRef
The prevalence of arm lymphedema after radiation treatment in patients with breast cancer
Kamonrat Sueangamiam, Kanisa Rongsriyam
Journal of Radiotherapy in Practice.2023;[Epub] CrossRef
The Use of Ultrasound Imaging for Upper Extremity Lymphedema after Breast Cancer: A Systematic Review
Elena Canales-Lachén, Ángel Asunsolo, Oscar J. Manrique, Javier Blázquez, Purificación Holguín, Andrés A. Maldonado
Journal of Reconstructive Microsurgery.2023; 39(02): 102. CrossRef
Risk factors of unilateral breast cancer-related lymphedema: an updated systematic review and meta-analysis of 84 cohort studies
Aomei Shen, Qian Lu, Xin Fu, Xiaoxia Wei, Liyuan Zhang, Jingru Bian, Wanmin Qiang, Dong Pang
Supportive Care in Cancer.2023;[Epub] CrossRef
Risk factors for the development of severe breast cancer-related lymphedema: a retrospective cohort study
Xiaozhen Liu, Kewang Sun, Hongjian Yang, Lingli Xia, Kefeng Lu, Xuli Meng, Yongfeng Li
BMC Cancer.2023;[Epub] CrossRef
Practical Approach to Establishing a Lymphedema Screening Program: Tips and Tricks
Derly C. Munoz, Sarah S. Virk, Oluwadamilola T. Oladeru, Pamela Clevenger, Tracy L. Hollen, Mariam W. Hanna, Lisa R. P. Spiguel
Current Breast Cancer Reports.2023; 15(3): 242. CrossRef
The impact of rehabilitation sport on breast cancer-related lymphoedema and quality of life
Bettina Boeer, Anna Seller, Birgitt Schoenfisch, Ute krainick-Strobel, Andreas Dietrich, Sara Y. Brucker, Diethelm Wallwiener, Andreas Niess, Markus Hahn
Archives of Gynecology and Obstetrics.2022; 307(5): 1529. CrossRef
The potential of gas plasma technology for targeting breast cancer
Sander Bekeschus, Fariba Saadati, Steffen Emmert
Clinical and Translational Medicine.2022;[Epub] CrossRef
Prediction of breast cancer-related lymphedema risk after postoperative radiotherapy via multivariable logistic regression analysis
Jae Sik Kim, Jin Ho Kim, Ji Hyun Chang, Do Wook Kim, Kyung Hwan Shin
Frontiers in Oncology.2022;[Epub] CrossRef
Invited Commentary from the Authors of: Kuruvilla AS, et al. Risk Factors Associated With Postmastectomy Breast Cancer Lymphedema: Amulticenter Retrospective Analysis
Annet S. Kuruvilla
Annals of Plastic Surgery.2022; 89(6): 716. CrossRef
Development and validation of a nomogram to predict the risk of breast cancer-related lymphedema among Chinese breast cancer survivors
Yan-fei Liu, Jun-E Liu, Yi Zhu, Yim Wah Mak, Hui Qiu, Li-hui Liu, Shen-shen Yang, Shao-hua Chen
Supportive Care in Cancer.2021; 29(9): 5435. CrossRef
Eliminating the Burden of Lymphedema in Cancer Patients Requiring Nodal Dissections Using Prophylactic Immediate Lymphatic Reconstruction – A Case Report and Review of the Literature
Abiye Mussie, Maria C. Medor, Sylia Mohand-Said, Andrea M. Ibrahim, Carolyn Nessim, Moein Momtazi
Plastic Surgery Case Studies.2021;[Epub] CrossRef
Factors predicting one or two sentinel lymph nodes to be accepted for sentinel lymph node biopsy alone after neoadjuvant therapy in initially node-positive breast cancer patients
Li-Wei Tsai, Yi-Hsuan Lee, Chiao Lo, Huang-Chun Lien, Ming-Yang Wang, I-Shiow Jan, Ruoh-Fang Yen, Fu-Chang Hu, Chiun-Sheng Huang
Surgical Oncology.2021; 39: 101667. CrossRef
Sentinel Lymph Node Biopsy in T3 and T4b Breast Cancer Patients: Analysis in a Tertiary Cancer Hospital and Systematic Literature Review
Idam de Oliveira-Junior, Eliana Aguiar Petri Nahas, Ana Cristina Cherem, Jorge Nahas-Neto, René Aloisio da Costa Vieira
Breast Care.2021; 16(1): 27. CrossRef
Histological features of skin and subcutaneous tissue in patients with breast cancer who have received neoadjuvant chemotherapy and their relationship to post-treatment edema
Ayako Nakagawa, Hiroshi Fujimoto, Takeshi Nagashima, Takafumi Sangai, Mamoru Takada, Takahito Masuda, Ryotaro Teranaka, Satoshi Ota, Jun Matsushima, Shinsuke Akita, Masayuki Ohtsuka
Breast Cancer.2020; 27(1): 77. CrossRef
Lymphedema Signs, Symptoms, and Diagnosis in Women Who Are in Minority and Low-Income Groups and Have Survived Breast Cancer
Ann Marie Flores, Jason Nelson, Lee Sowles, Rebecca G Stephenson, Kathryn Robinson, Andrea Cheville, Antoinette P Sander, William J Blot
Physical Therapy.2020; 100(3): 487. CrossRef
Prevalence of obstructive sleep apnea syndrome in patients with lymphedema referred for complete decongestive therapy
Côme Roux, Béatrice Villemur, Brigitte Giovannoni, Lucie Koeyemelk, Monique Mendelson, Meriem Benmerad, Marie Joyeux-Faure, Renaud Tamisier, Jean-Louis Pepin
Journal of Vascular Surgery: Venous and Lymphatic Disorders.2020; 8(1): 137. CrossRef
The results of the intensive phase of complete decongestive therapy and the determination of predictive factors for response to treatment in patients with breast cancer related‐lymphedema
Dilek Keskin, Meltem Dalyan, Sibel Ünsal‐Delialioğlu, Ülkü Düzlü‐Öztürk
Cancer Reports.2020;[Epub] CrossRef
A scoring system for predicting the risk of breast cancer-related lymphedema
Fenglian Li, Qian Lu, Sanli Jin, Quanping Zhao, Xueying Qin, Shuai Jin, Lichuan Zhang
International Journal of Nursing Sciences.2020; 7(1): 21. CrossRef
Lymphedema and Lymphovenous Bypass: Perioperative Nursing Implications
Lori A. Whitnell
AORN Journal.2020; 111(2): 187. CrossRef
Who Will Continuously Depend on Compression to Control Persistent or Progressive Breast Cancer-Related Lymphedema Despite 2 Years of Conservative Care?
Chul Jung, JaYoung Kim, Yu Jin Seo, Kyeong Joo Song, Ma. Nessa Gelvosa, Jin Geun Kwon, Changsik John Pak, Hyunsuk Peter Suh, Joon Pio Hong, Hwa Jung Kim, Jae Yong Jeon
Journal of Clinical Medicine.2020; 9(11): 3640. CrossRef
Role of p53 as a prognostic marker in breast carcinoma and its correlation with tumor size, tumor grade and lymph node metastasis
Alok Mohan, Bharat Jindal, Rajender Kumar Thakral, Vaseem Ansari, Veena K Sharma
Indian Journal of Pathology and Oncology.2020; 7(3): 378. CrossRef
Risk factors and prediction model for persistent breast-cancer-related lymphedema: a 5-year cohort study
I-Wen Penn, Yue-Cune Chang, Eric Chuang, Chi-Ming Chen, Chi-Feng Chung, Chia-Yu Kuo, Tien-Yow Chuang
Supportive Care in Cancer.2019; 27(3): 991. CrossRef
Progressive resistance training to prevent arm lymphedema in the first year after breast cancer surgery: Results of a randomized controlled trial
Gunn Ammitzbøll, Christoffer Johansen, Charlotte Lanng, Elisabeth Wreford Andersen, Niels Kroman, Bo Zerahn, Ole Hyldegaard, Merete Celano Wittenkamp, Susanne Oksbjerg Dalton
Cancer.2019; 125(10): 1683. CrossRef
Frequency and risk factors for arm lymphedema after multimodal breast-conserving treatment of nodal positive breast Cancer – a long-term observation
Julia Rupp, Catarina Hadamitzky, Christoph Henkenberens, Hans Christiansen, Diana Steinmann, Frank Bruns
Radiation Oncology.2019;[Epub] CrossRef
Elevated levels of eEF1A2 protein expression in triple negative breast cancer relate with poor prognosis
Fabiola Giudici, Elisabetta Petracci, Oriana Nanni, Cristina Bottin, Maurizio Pinamonti, Fabrizio Zanconati, Bruna Scaggiante, Aamir Ahmad
PLOS ONE.2019; 14(6): e0218030. CrossRef
Introduction of the Lymphedema Action Plan (LeAP): Clinical Advancement in Proactive Lymphedema Care
Renata Beaman
Rehabilitation Oncology.2019; 37(3): 122. CrossRef
Profile of women with lymphedema after breast cancer treatment
Thais de Oliveira Gozzo, Gabriela Aguado, Aniele Tomadon, Marislei Sanches Panobianco, Maria Antonieta Spinoso Prado
Escola Anna Nery.2019;[Epub] CrossRef
Lymphatic Microsurgical Preventing Healing Approach (LYMPHA) for Prevention of Breast Cancer-Related Lymphedema—a Preliminary Report
Juhi Agrawal, Sandeep Mehta, Ashish Goel, Pankaj Kumar Pande, Kapil Kumar
Indian Journal of Surgical Oncology.2018; 9(3): 369. CrossRef
Progressive strength training to prevent LYmphoedema in the first year after breast CAncer – the LYCA feasibility study
Gunn Ammitzbøll, Charlotte Lanng, Niels Kroman, Bo Zerahn, Ole Hyldegaard, Klaus Kaae Andersen, Christoffer Johansen, Susanne Oksbjerg Dalton
Acta Oncologica.2017; 56(2): 360. CrossRef
Association between adjuvant docetaxel-based chemotherapy and breast cancer-related lymphedema
Wen Zhu, Dan Li, Xiaoqin Li, Jin Ren, Wenqi Chen, Hangang Gu, Yongqian Shu, Deqiang Wang
Anti-Cancer Drugs.2017; 28(3): 350. CrossRef
P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients
Yunbao Pan, Yufen Yuan, Guoshi Liu, Yongchang Wei, William B. Coleman
PLOS ONE.2017; 12(2): e0172324. CrossRef
Considerations for Clinicians in the Diagnosis, Prevention, and Treatment of Breast Cancer-Related Lymphedema: Recommendations from a Multidisciplinary Expert ASBrS Panel
Sarah A. McLaughlin, Alicia C. Staley, Frank Vicini, Paul Thiruchelvam, Nancy A. Hutchison, Jane Mendez, Fiona MacNeill, Stanley G. Rockson, Sarah M. DeSnyder, Suzanne Klimberg, Michael Alatriste, Francesco Boccardo, Mark L. Smith, Sheldon M. Feldman
Annals of Surgical Oncology.2017; 24(10): 2818. CrossRef
Current and future perspectives on the evaluation, prevention and conservative management of breast cancer related lymphoedema: A best practice guideline
Nick Gebruers, Hanne Verbelen, Tessa De Vrieze, Lore Vos, Nele Devoogdt, Lore Fias, Wiebren Tjalma
European Journal of Obstetrics & Gynecology and Reproductive Biology.2017; 216: 245. CrossRef
Changes in volume and incidence of lymphedema during and after treatment with docetaxel, doxorubicin, and cyclophosphamide (TAC) in patients with breast cancer
Janine T. Hidding, Carien H. G. Beurskens, Philip J. van der Wees, Wilmy C. A. M. Bos, Maria W. G. Nijhuis-van der Sanden, Hanneke W. M. van Laarhoven
Supportive Care in Cancer.2017;[Epub] CrossRef
Palliative surgery for giant mucinous carcinoma of the breast in an elderly patient: A rare case report
Haruko Takuwa, Wakako Tsuji, Fumiaki Yotsumoto
Molecular and Clinical Oncology.2017; 7(4): 609. CrossRef
Update December 2016
Francine Blei
Lymphatic Research and Biology.2016; 14(4): 240. CrossRef

12,688 View
246 Download
45 Web of Science
41 Crossref

Erratum

ERRATUM: Role of Chemotherapy in Stage II Nasopharyngeal Carcinoma Treated with Curative Radiotherapy: Min Kyu Kang, Dongryul Oh, Kwan Ho Cho, Sung Ho Moon, Hong-Gyun Wu, Dae-Seog Heo, Yong Chan Ahn, Keunchil Park, Hyo Jung Park, Jun Su Park, Ki Chang Keum, Jihye Cha, Jun Won Kim, Yeon-Sil Kim, Jin Hyoung Kang, Young-Taek Oh, Ji-Yoon Kim, Sung Hwan Kim, Jin-Hee Kim, Chang Geol Lee; Cancer Res Treat. 2016;48(1):425-425. Published online January 10, 2016; DOI: https://doi.org/10.4143/crt.2014.141.2; Corrects: Cancer Res Treat 2015;47(4):871

PDF PubReader ePub

9,323 View
91 Download
1 Web of Science

Original Articles

The Role of Neoadjuvant Chemotherapy in the Treatment of Nasopharyngeal Carcinoma: A Multi-institutional Retrospective Study (KROG 11-06) Using Propensity Score Matching Analysis: Jin Ho Song, Hong-Gyun Wu, Bhum Suk Keam, Jeong Hun Hah, Yong Chan Ahn, Dongryul Oh, Jae Myoung Noh, Hyo Jung Park, Chang Geol Lee, Ki Chang Keum, Jihye Cha, Kwan Ho Cho, Sung Ho Moon, Ji-Yoon Kim, Woong-Ki Chung, Young Taek Oh, Won Taek Kim, Moon-June Cho, Chul Seung Kay, Yeon-Sil Kim; Cancer Res Treat. 2016;48(3):917-927. Published online December 28, 2015; DOI: https://doi.org/10.4143/crt.2015.265

Abstract PDF PubReader ePub

Purpose
We compared the treatment results and toxicity in nasopharyngeal carcinoma (NPC) patients treated with concurrent chemotherapy (CCRT) alone (the CRT arm) or neoadjuvant chemotherapy followed by CCRT (the NCT arm). Materials and Methods A multi-institutional retrospective study was conducted to review NPC patterns of care and treatment outcome. Data of 568 NPC patients treated by CCRT alone or by neoadjuvant chemotherapy followed by CCRT were collected from 15 institutions. Patients in both treatment arms were matched using the propensity score matching method, and the clinical outcomes were analyzed.
Results
After matching, 300 patients (150 patients in each group) were selected for analysis. Higher 5-year locoregional failure-free survival was observed in the CRT arm (85% vs. 72%, p=0.014). No significant differences in distant failure-free survival (DFFS), disease-free survival (DFS), and overall survival were observed between groups. In subgroup analysis, the NCT arm showed superior DFFS and DFS in stage IV patients younger than 60 years. No significant difference in compliance and toxicity was observed between groups, except the radiation therapy duration was slightly shorter in the CRT arm (50.0 days vs. 53.9 days, p=0.018). Conclusion This study did not show the superiority of NCT followed by CCRT over CCRT alone. Because NCT could increase the risk of locoregional recurrences, it can only be considered in selected young patients with advanced stage IV disease. The role of NCT remains to be defined and should not be viewed as the standard of care.

Citations

Citations to this article as recorded by

Age is a significant biomarker for the selection of neoadjuvant chemotherapy plus radiotherapy versus concurrent chemoradiotherapy in patients with advanced nasopharyngeal carcinoma
Yihong Lin, Xiongbin Yu, Linbin Lu, Hong Chen, Junxian Wu, Yaying Chen, Qin Lin, Xuewen Wang, Xi Chen, Xiong Chen
Cancer Biomarkers.2023; 37(1): 1. CrossRef
Effect of Induction Chemotherapy in Nasopharyngeal Carcinoma: An Updated Meta-Analysis
Shan-Shan Yang, Jian-Gui Guo, Jia-Ni Liu, Zhi-Qiao Liu, En-Ni Chen, Chun-Yan Chen, Pu-Yun OuYang, Fei Han, Fang-Yun Xie
Frontiers in Oncology.2021;[Epub] CrossRef
Concurrent chemoradiotherapy with additional chemotherapy for nasopharyngeal carcinoma: A pooled analysis of propensity score‐matching studies
Minmin Li, Bin Zhang, Qiuying Chen, Lu Zhang, Xiaokai Mo, Zhuozhi Chen, Zhe Jin, Luyan Chen, Jingjing You, Shuixing Zhang
Head & Neck.2021; 43(6): 1912. CrossRef
Longitudinal Assessment of Intravoxel Incoherent Motion Diffusion Weighted Imaging in Evaluating the Radio-sensitivity of Nasopharyngeal Carcinoma Treated with Intensity-Modulated Radiation Therapy
Youping Xiao, Ying Chen, Yunbin Chen, Zhuangzhen He, Yiqi Yao, Jianji Pan
Cancer Research and Treatment.2019; 51(1): 345. CrossRef
Less is more: role of additional chemotherapy to concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal cancer management
Yong Chan Ahn
Radiation Oncology Journal.2019; 37(2): 67. CrossRef
A Pairwise Meta-Analysis of Induction Chemotherapy in Nasopharyngeal Carcinoma
Pu-Yun OuYang, Xiao-Min Zhang, Xing-Sheng Qiu, Zhi-Qiao Liu, Lixia Lu, Yuan-Hong Gao, Fang-Yun Xie
The Oncologist.2019; 24(4): 505. CrossRef
Induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A systematic review and meta-analysis
Teng Hwee Tan, Yu Yang Soon, Timothy Cheo, Francis Ho, Lea Choung Wong, Jeremy Tey, Ivan W.K. Tham
Radiotherapy and Oncology.2018; 129(1): 10. CrossRef
Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma
Jiraporn Setakornnukul, Kullathorn Thephamongkhol
BMC Cancer.2018;[Epub] CrossRef
TPF induction chemotherapy followed by concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma: Long term results of a Tunisian series
N. Toumi, W. Ben Kridis, W. Mnejja, R. Bouzguenda, A. Khanfir, A. Ghorbel, J. Daoud, M. Frikha
Cancer/Radiothérapie.2018; 22(3): 216. CrossRef
Does concurrent chemoradiotherapy preceded by chemotherapy improve survival in locally advanced nasopharyngeal cancer patients? Experience from Ghana
Joel Yarney, Naa A. Aryeetey, Alice Mensah, Emmanuel D. Kitcher, Verna Vanderpuye, Charles Aidoo, Kenneth Baidoo
Cancers of the Head & Neck.2017;[Epub] CrossRef
Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in nasopharyngeal carcinoma patients with cervical nodal necrosis
Mei Lan, Chunyan Chen, Ying Huang, Li Tian, Zhijun Duan, Fei Han, Junfang Liao, Meiling Deng, Terence T. Sio, Anussara Prayongrat, Lie Zheng, Shaoxiong Wu, Taixiang Lu
Scientific Reports.2017;[Epub] CrossRef
A retrospective paired study: efficacy and toxicity of nimotuzumab versus cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma
H. M. Li, P. Li, Y. J. Qian, X. Wu, L. Xie, F. Wang, H. Zhang, L. Liu
BMC Cancer.2016;[Epub] CrossRef

13,077 View
150 Download
13 Web of Science
12 Crossref

Role of Chemotherapy in Stage II Nasopharyngeal Carcinoma Treated with Curative Radiotherapy: Min Kyu Kang, Dongryul Oh, Kwan Ho Cho, Sung Ho Moon, Hong-Gyun Wu, Dae-Seog Heo, Yong Chan Ahn, Keunchil Park, Hyo Jung Park, Jun Su Park, Ki Chang Keum, Jihye Cha, Jun Won Kim, Yeon-Sil Kim, Jin Hyoung Kang, Young-Taek Oh, Ji-Yoon Kim, Sung Hwan Kim, Jin-Hee Kim, Chang Geol Lee; Cancer Res Treat. 2015;47(4):871-878. Published online February 13, 2015; DOI: https://doi.org/10.4143/crt.2014.141; Correction in: Cancer Res Treat 2016;48(1):425

Abstract PDF PubReader ePub

Purpose
To define the role of neoadjuvant and concurrent chemotherapy in stage II nasopharyngeal carcinoma, we compared the treatment outcomes of patients treated with curative radiotherapy with or without chemotherapy. Materials and Methods From 2004 to 2011, 138 patients with American Joint Committee on Cancer (AJCC) 2002 stage II nasopharyngeal carcinoma were treated with curative radiotherapy in 12 hospitals in South Korea. Treatment methods included radiotherapy alone in 34 patients, neoadjuvant chemotherapy followed by radiotherapy alone in seven, concurrent chemoradiotherapy in 80, and neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in 17. Adjuvant chemotherapy was used in 42 patients. Total radiation dose ranged from 64 Gy to 74.2 Gy (median, 70 Gy).
Results
Median follow-up was 48 months (range, 7 to 97 months) for all patients. At the last followup, 13 patients had died and 32 had experienced treatment failure; locoregional failure occurred in 14, distant failure in 16, and both in two. Five-year locoregional relapse-free survival, distant metastasis-free survival, progression-free survival, and overall survival were 86.2%, 85.5%, 74.4%, and 88.2%, respectively. Multivariate analyses showed that the significant prognostic factors were concurrent chemotherapy and N stage for locoregional relapse-free survival, concurrent chemotherapy for progression-free survival, and age and N stage for overall survival. Neither neoadjuvant nor concurrent chemotherapy improved distant metastasis-free survival. Conclusion Concurrent chemotherapy significantly improved 5-year locoregional relapse-free survival and progression-free survival in stage II nasopharyngeal carcinoma. However, neoadjuvant chemotherapy failed to improve either.

Citations

Citations to this article as recorded by

Concurrent chemoradiotherapy versus radiotherapy alone in older patients with stage II nasopharyngeal carcinoma after intensity-modulated radiotherapy: A propensity score-matched cohort study
Fang Wang, Lu Zhou, Li-Jun Zhang, Chang-Bin Xie, Zhi-Wei Liao, Xiao-Dan Lin, Yue-Feng Wen
Radiotherapy and Oncology.2024; 191: 110081. CrossRef
A Systematic Review and Meta-Analysis of Studies Comparing Concurrent Chemoradiotherapy With Radiotherapy Alone in the Treatment of Stage II Nasopharyngeal Carcinoma
Yao-Can Xu, Kai-Hua Chen, Zhong-Guo Liang, Xiao-Dong Zhu
Frontiers in Oncology.2022;[Epub] CrossRef
MRI-identified multidimensional nodal features predict survival and concurrent chemotherapy benefit for stage II nasopharyngeal carcinoma
Yang Liu, Jianghu Zhang, Jingbo Wang, Runye Wu, Xiaodong Huang, Kai Wang, Yuan Qu, Xuesong Chen, Yexiong Li, Ye Zhang, Junlin Yi
Radiology and Oncology.2022; 56(4): 479. CrossRef
The efficacy of chemotherapy in survival of stage II nasopharyngeal carcinoma
Xin-Bin Pan, Ling Li, Song Qu, Long Chen, Shi-Xiong Liang, Xiao-Dong Zhu
Oral Oncology.2020; 101: 104520. CrossRef
Survival of stage II nasopharyngeal carcinoma patients with or without concurrent chemotherapy: A propensity score matching study
Di‐Han Liu, Xiao‐Yu Zhou, You‐Guang Pan, Si Chen, Zheng‐Hao Ye, Gang‐Dong Chen
Cancer Medicine.2020; 9(4): 1287. CrossRef
Concurrent Chemoradiotherapy With or Without Induction Chemotherapy for Patients with Stage II Nasopharyngeal Carcinoma: An Update
Ting Jin, Qun Zhang, Dong-Hua Luo, Feng Jiang, Qi-Feng Jin, Yuan-Yuan Chen, Xiao-Zhong Chen, Wei-Min Mao
Translational Oncology.2020; 13(1): 25. CrossRef
Predictive factors of chemotherapy use in stage II nasopharyngeal carcinoma
Xin-Bin Pan, Shi-Ting Huang, Kai-Hua Chen, Yan-Ming Jiang, Xiao-Dong Zhu
Medicine.2019; 98(7): e14512. CrossRef
The role of chemotherapy in the treatment of stage II nasopharyngeal carcinoma: Retrospective analysis of the national cancer database
Zaheer Ahmed, Lara Kujtan, Kevin Kennedy, Valerie Wood, David Schomas, Janakiraman Subramanian
Cancer Medicine.2019; 8(4): 1500. CrossRef
Patterns of Failure and Survival Trends in 3,808 Patients with Stage II Nasopharyngeal Carcinoma Diagnosed from 1990 to 2012: A Large-Scale Retrospective Cohort Study
Xue-Song Sun, Di-Han Liu, Sai-Lan Liu, Qiu-Yan Chen, Shan-Shan Guo, Yue-Feng Wen, Li-Ting Liu, Hao-Jun Xie, Qing-Nan Tang, Yu-Jing Liang, Xiao-Yun Li, Jin-Jie Yan, Ming-Huang Hong, Jun Ma, Lin-Quan Tang, Hai-Qiang Mai
Cancer Research and Treatment.2019; 51(4): 1449. CrossRef
Combined chemoradiation vs radiation therapy alone in stage-II nasopharyngeal carcinoma: A meta-analysis of the published literature
Sufang Wang, Shan Li, Liangfang Shen
Current Problems in Cancer.2018; 42(3): 302. CrossRef
The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era
Pei-Jing Li, Hao-Yuan Mo, Dong-Hua Luo, Wei-Han Hu, Ting Jin
Oral Oncology.2018; 85: 95. CrossRef
Concurrent chemoradiotherapy degrades the quality of life of patients with stage II nasopharyngeal carcinoma as compared to radiotherapy
Xin-Bin Pan, Shi-Ting Huang, Kai-Hua Chen, Yan-Ming Jiang, Jia-Lin Ma, Song Qu, Ling Li, Long Chen, Xiao-Dong Zhu
Oncotarget.2017; 8(8): 14029. CrossRef
Chemotherapy use and survival in stage II nasopharyngeal carcinoma
Xin-Bin Pan, Shi-Ting Huang, Kai-Hua Chen, Xiao-Dong Zhu
Oncotarget.2017; 8(60): 102573. CrossRef
Long-term survival of nasopharyngeal carcinoma patients with Stage II in intensity-modulated radiation therapy era
Qiaojuan Guo, Tianzhu Lu, Shaojun Lin, Jingfeng Zong, Zhuhong Chen, Xiaofei Cui, Yu Zhang, Jianji Pan
Japanese Journal of Clinical Oncology.2016; 46(3): 241. CrossRef
Comparison of the efficacy between concurrent chemoradiotherapy with or without adjuvant chemotherapy and intensity-modulated radiotherapy alone for stage II nasopharyngeal carcinoma
Kai-Hua Chen, Xiao-Dong Zhu, Ling Li, Song Qu, Zhen-Qiang Liang, Xia Liang, Xin-Bin Pan, Zhong-Guo Liang, Yan-Ming Jiang
Oncotarget.2016; 7(42): 69041. CrossRef
Propensity score matching analysis of cisplatin-based concurrent chemotherapy in low risk nasopharyngeal carcinoma in the intensity-modulated radiotherapy era
Lu-Ning Zhang, Yuan-Hong Gao, Xiao-Wen Lan, Jie Tang, Zhen Su, Jun Ma, Wuguo Deng, Pu-Yun OuYang, Fang-Yun Xie
Oncotarget.2015; 6(41): 44019. CrossRef

13,940 View
103 Download
23 Web of Science
16 Crossref

Breast Cancer–Related Lymphedema after Neoadjuvant Chemotherapy: Myungsoo Kim, In Hae Park, Keun Seok Lee, Jungsil Ro, So-Youn Jung, Seeyoun Lee, Han-Sung Kang, Eun Sook Lee, Tae Hyun Kim, Kwan Ho Cho, Kyung Hwan Shin; Cancer Res Treat. 2015;47(3):416-423. Published online November 17, 2014; DOI: https://doi.org/10.4143/crt.2014.079

Abstract PDF PubReader ePub

Purpose
The risk for lymphedema (LE) after neoadjuvant chemotherapy (NCT) in breast cancer patients has not been fully understood thus far. This study is conducted to investigate the incidence and time course of LE after NCT. Materials and Methods A total of 313 patients with clinically node-positive breast cancer who underwent NCT followed by surgery with axillary lymph node (ALN) dissection from 2004 to 2009 were retrospectively analyzed. All patients received breast and supraclavicular radiation therapy (SCRT). The determination of LE was based on both objective and subjective methods, as part of a prospective database. Results At a median follow-up of 5.6 years, 132 patients had developed LE: 88 (28%) were grade 1; 42 (13%) were grade 2; and two (1%) were grade 3. The overall 5-year cumulative incidence of LE was 42%. LE first occurred within 6 months after surgery in 62%; 1 year in 77%; 2 years in 91%; and 3 years in 96%. In a multivariate analysis, age (hazard ratio [HR], 1.66; p < 0.01) and the number of dissected ALNs (HR, 1.68; p < 0.01) were independent risk factors for LE. Patients with both of these risk factors showed a significantly higher 5-year cumulative incidence of LE compared with patients with no or one risk factor (61% and 37%, respectively; p < 0.001). The addition of adjuvant chemotherapy did not significantly correlate with LE. Conclusion LE after NCT, surgery, and SCRT developed early after treatment, and with a high incidence rate. More frequent surveillance of arm swelling may be necessary in patients after NCT, especially during the first few years of follow-up.

Citations

Citations to this article as recorded by

Impact of neoadjuvant chemotherapy on breast cancer-related lymphedema after axillary lymph node dissection: a retrospective cohort study
Miaomiao Jia, Lihui Pan, Haibo Yang, Jinnan Gao, Fan Guo
Breast Cancer Research and Treatment.2024; 204(2): 223. CrossRef
Incidence and risk factors of breast cancer-related lymphedema in Korea: A nationwide retrospective cohort study
Ha Rim Ahn, Hyeong Eun Jeong, Choyun Jeong, Sang Yull Kang, Sung Hoo Jung, Hyun Jo Youn, Jong Seung Kim
International Journal of Surgery.2024;[Epub] CrossRef
Incidence of lymphedema related to various cancers
Marie-Eve Letellier, Marize Ibrahim, Anna Towers, Geneviève Chaput
Medical Oncology.2024;[Epub] CrossRef
Age as a risk factor for breast cancer-related lymphedema: a systematic review
Gunel Guliyeva, Maria T. Huayllani, Daniel Boczar, Francisco R. Avila, Xiaona Lu, Antonio Jorge Forte
Journal of Cancer Survivorship.2023; 17(1): 246. CrossRef
Risk factors of unilateral breast cancer-related lymphedema: an updated systematic review and meta-analysis of 84 cohort studies
Aomei Shen, Qian Lu, Xin Fu, Xiaoxia Wei, Liyuan Zhang, Jingru Bian, Wanmin Qiang, Dong Pang
Supportive Care in Cancer.2023;[Epub] CrossRef
Beyond cardiomyocytes: Cellular diversity in the heart's response to exercise
Lena E. Trager, Margaret Lyons, Alexandra Kuznetsov, Cedric Sheffield, Kangsan Roh, Rebecca Freeman, James Rhee, J. Sawalla Guseh, Haobo Li, Anthony Rosenzweig
Journal of Sport and Health Science.2023; 12(4): 423. CrossRef
Managing the Morbidity
Giacomo Montagna, Andrea V. Barrio
Surgical Oncology Clinics of North America.2023; 32(4): 705. CrossRef
Risk of Lymphedema and Death after Lymph Node Dissection with Neoadjuvant and Adjuvant Treatments in Patients with Breast Cancer: An Eight-Year Nationwide Cohort Study
Ye-Seul Lee, Yu-Cheol Lim, Jiyoon Yeo, Song-Yi Kim, Yoon Jae Lee, In-Hyuk Ha
Healthcare.2023; 11(13): 1833. CrossRef
Discussion: Variable Anatomy of the Lateral Upper Arm Lymphatic Channel: An Anatomical Risk Factor for Breast Cancer–Related Lymphedema
Mengfan Wu, Shailesh Agarwal
Plastic & Reconstructive Surgery.2023; 152(2): 430. CrossRef
Breast cancer treatment‐related arm lymphoedema and morbidity: A 6‐year experience in an Australian tertiary breast centre
Yang Yang Huang, Pei Yinn Toh, Catherine Hunt, Joshua Tzi Wei Lin, Roshi Kamyab, Ananda Kallyani Ponniah
Asia-Pacific Journal of Clinical Oncology.2022; 18(1): 109. CrossRef
Cancer Rehabilitation Fact Sheet in Korea
Jin A Yoon, Bo Young Hong
Annals of Rehabilitation Medicine.2022; 46(4): 155. CrossRef
Burden of lymphedema in long‐term breast cancer survivors by race and age
Yumeng Ren, Michael A. Kebede, Adeyemi A. Ogunleye, Marc A. Emerson, Kelly R. Evenson, Lisa A. Carey, Sandra C. Hayes, Melissa A. Troester
Cancer.2022; 128(23): 4119. CrossRef
Acquired lymphedema: Molecular contributors and future directions for developing intervention strategies
Ika Nurlaila, Kangsan Roh, Chang-Hwan Yeom, Hee Kang, Sukchan Lee
Frontiers in Pharmacology.2022;[Epub] CrossRef
Prediction of breast cancer-related lymphedema risk after postoperative radiotherapy via multivariable logistic regression analysis
Jae Sik Kim, Jin Ho Kim, Ji Hyun Chang, Do Wook Kim, Kyung Hwan Shin
Frontiers in Oncology.2022;[Epub] CrossRef
Histological features of skin and subcutaneous tissue in patients with breast cancer who have received neoadjuvant chemotherapy and their relationship to post-treatment edema
Ayako Nakagawa, Hiroshi Fujimoto, Takeshi Nagashima, Takafumi Sangai, Mamoru Takada, Takahito Masuda, Ryotaro Teranaka, Satoshi Ota, Jun Matsushima, Shinsuke Akita, Masayuki Ohtsuka
Breast Cancer.2020; 27(1): 77. CrossRef
A scoring system for predicting the risk of breast cancer-related lymphedema
Fenglian Li, Qian Lu, Sanli Jin, Quanping Zhao, Xueying Qin, Shuai Jin, Lichuan Zhang
International Journal of Nursing Sciences.2020; 7(1): 21. CrossRef
Body Mass Index as a Major Risk Factor for Severe Breast Cancer-Related Lymphedema
Hélène Leray, Julie Malloizel-Delaunay, Amélie Lusque, Elodie Chantalat, Léonard Bouglon, Charlotte Chollet, Benoit Chaput, Barbara Garmy-Susini, Alexandra Yannoutsos, Charlotte Vaysse
Lymphatic Research and Biology.2020; 18(6): 510. CrossRef
Factors Associated With Lymphedema in Women With Node-Positive Breast Cancer Treated With Neoadjuvant Chemotherapy and Axillary Dissection
Jane M. Armer, Karla V. Ballman, Linda McCall, Pamela L. Ostby, Eris Zagar, Henry M. Kuerer, Kelly K. Hunt, Judy C. Boughey
JAMA Surgery.2019; 154(9): 800. CrossRef
Breast deformation during the course of radiotherapy: The need for an additional outer margin
J. Seppälä, K. Vuolukka, T. Virén, J. Heikkilä, J.T.J. Honkanen, A. Pandey, A. Al-Gburi, M. Shah, S. Sefa, T. Koivumäki
Physica Medica.2019; 65: 1. CrossRef
Current and future perspectives on the evaluation, prevention and conservative management of breast cancer related lymphoedema: A best practice guideline
Nick Gebruers, Hanne Verbelen, Tessa De Vrieze, Lore Vos, Nele Devoogdt, Lore Fias, Wiebren Tjalma
European Journal of Obstetrics & Gynecology and Reproductive Biology.2017; 216: 245. CrossRef
Incidence and risk factors of lymphedema after breast cancer treatment: 10 years of follow-up
Ana Carolina Padula Ribeiro Pereira, Rosalina Jorge Koifman, Anke Bergmann
The Breast.2017; 36: 67. CrossRef
Risk factors for lymphoedema in women with breast cancer: A large prospective cohort
S.L. Kilbreath, K.M. Refshauge, J.M. Beith, L.C. Ward, O.A. Ung, E.S. Dylke, J.R. French, J. Yee, L. Koelmeyer, K. Gaitatzis
The Breast.2016; 28: 29. CrossRef
Identification of Prognostic Risk Factors for Transient and Persistent Lymphedema after Multimodal Treatment for Breast Cancer
Myungsoo Kim, Kyung Hwan Shin, So-Youn Jung, Seeyoun Lee, Han-Sung Kang, Eun Sook Lee, Seung Hyun Chung, Yeon-Joo Kim, Tae Hyun Kim, Kwan Ho Cho
Cancer Research and Treatment.2016; 48(4): 1330. CrossRef
Local Treatment of Breast Cancer
Joanne Lester
Seminars in Oncology Nursing.2015;[Epub] CrossRef
Discrepant Trajectories of Impairment, Activity, and Participation Related to Upper-Limb Function in Patients With Breast Cancer
Eun Joo Yang, Eunyoung Kang, Sung-Won Kim, Jae-Young Lim
Archives of Physical Medicine and Rehabilitation.2015; 96(12): 2161. CrossRef

14,777 View
120 Download
27 Web of Science
25 Crossref

Radiation-induced Necrosis Deteriorating Neurological Symptoms and Mimicking Progression of Brain Metastasis after Stereotactic-guided Radiotherapy: Young Zoon Kim, Dae Yong Kim, Heon Yoo, Hee Seok Yang, Sang Hoon Shin, Eun Kyung Hong, Kwan Ho Cho, Seung Hoon Lee; Cancer Res Treat. 2007;39(1):16-21. Published online March 31, 2007; DOI: https://doi.org/10.4143/crt.2007.39.1.16

Abstract PDF PubReader ePub

Purpose

Although radiation-induced necrosis (RIN) is not a tumor in itself, the lesion progressively enlarges with mass effects and diffuse peritumoral edema in a way that resembles neoplasm. To identify the RIN that mimics progression of brain metastasis, we performed surgical resections of symptomatic RIN lesions.

Meterials and Methods

From June 2003 to December 2005, 7 patients received stereotactic-guided radiotherapy (SRT) for metastatic brain tumor, and they later underwent craniotomy and tumor resection due to the progressive mass effects and the peritumoral edema that caused focal neurological deficit. On MR imaging, a ring-like enhanced single lesion with massive peritumoral edema could not be distinguished from progression of brain metastasis.

Results

Four patients had non-small cell lung cancer, 2 patients had colorectal cancer and 1 patient had renal cell carcinoma. The mean tumor volume was 8.7 ml (range: 3.0~20.7 ml). The prescribed dose of SRT was 30 Gy with 4 fractions for one patient, 18 Gy for two patients and 20 Gy for the other four patients. The four patients who received SRT with a dose of 20 Gy had RIN with or without microscopic residual tumor cells.

Conclusions

Early detection of recurrent disease after radiotherapy and identifying radiation-induced tissue damage are important for delivering adequate treatment. Therefore, specific diagnostic tools that can distinguish RIN from progression of metastatic brain tumor need to be developed.

Citations

Citations to this article as recorded by

Salvage craniotomy for treatment-refractory symptomatic cerebral radiation necrosis
Ashish H Shah, Anil K Mahavadi, Alexis Morell, Daniel G Eichberg, Evan Luther, Christopher A Sarkiss, Alexa Semonche, Michael E Ivan, Ricardo J Komotar
Neuro-Oncology Practice.2020; 7(1): 94. CrossRef
OAR sparing 3D radiotherapy planning supported by fMRI brain mapping investigations
Gábor Opposits, Csaba Aranyi, Csaba Glavák, Zsolt Cselik, Lajos Trón, Dávid Sipos, Janaki Hadjiev, Ervin Berényi, Imre Repa, Miklós Emri, Árpád Kovács
Medical Dosimetry.2020; 45(4): e1. CrossRef
The Role of Navigated Transcranial Magnetic Stimulation Motor Mapping in Adjuvant Radiotherapy Planning in Patients With Supratentorial Brain Metastases
Maximilian J. Schwendner, Nico Sollmann, Christian D. Diehl, Markus Oechsner, Bernhard Meyer, Sandro M. Krieg, Stephanie E. Combs
Frontiers in Oncology.2018;[Epub] CrossRef
Impact of the radiosurgery prescription dose on the local control of small (2 cm or smaller) brain metastases
Alireza M. Mohammadi, Jason L. Schroeder, Lilyana Angelov, Samuel T. Chao, Erin S. Murphy, Jennifer S. Yu, Gennady Neyman, Xuefei Jia, John H. Suh, Gene H. Barnett, Michael A. Vogelbaum
Journal of Neurosurgery.2017; 126(3): 735. CrossRef
Nonthermal ablation in the rat brain using focused ultrasound and an ultrasound contrast agent: long-term effects
Nathan McDannold, Yongzhi Zhang, Natalia Vykhodtseva
Journal of Neurosurgery.2016; 125(6): 1539. CrossRef
Analysis of risk and predictors of brain radiation necrosis after radiosurgery
Hongqing Zhuang, Yi Zheng, Junjie Wang, Joe Y. Chang, Xiaoguang Wang, Zhiyong Yuan, Ping Wang
Oncotarget.2016; 7(7): 7773. CrossRef
Discriminating radiation necrosis from tumor progression in gliomas: a systematic review what is the best imaging modality?
Ashish H. Shah, Brian Snelling, Amade Bregy, Payal R. Patel, Danoushka Tememe, Rita Bhatia, Evelyn Sklar, Ricardo J. Komotar
Journal of Neuro-Oncology.2013; 112(2): 141. CrossRef
Comparison of Swallowing Functions Between Brain Tumor and Stroke Patients
Dae Hwan Park, Min Ho Chun, Sook Joung Lee, Yoon Bum Song
Annals of Rehabilitation Medicine.2013; 37(5): 633. CrossRef

10,418 View
60 Download
8 Crossref

Evaluation of Parotid Gland Function following Intensity Modulated Radiation Therapy for Head and Neck Cancer: Seok Ho Lee, Tae Hyun Kim, Joo Young Kim, Sung Yong Park, Hong Ryull Pyo, Kyung Hwan Shin, Dae Yong Kim, Joo Young Kim, Kwan Ho Cho; Cancer Res Treat. 2006;38(2):84-91. Published online April 30, 2006; DOI: https://doi.org/10.4143/crt.2006.38.2.84

Abstract PDF PubReader ePub

Purpose

This study was undertaken to determine the parotid gland tolerance dose levels following intensity modulated radiation therapy (IMRT) for treating patients who suffered with head and neck cancer.

Materials and Methods

From February 2003 through June 2004, 34 head and neck patients with 6 months of follow-up were evaluated for xerostomia after being treated by IMRT. Their median age was 59 years (range: 29~78). Xerostomia was assessed using a 4-question xerostomia questionnaire score (XQS) and a test for the salivary flow rates (unstimulated and stimulated: USFR and SSFR, respectively). The patients were also given a validated LENT SOMA scale (LSS) questionnaire. Evaluations were performed before IMRT and at 1, 3 and 6 months after IMRT.

Results

All 34 patients showed significant changes in the XQS, LSS and Salivary Flow rates (USFR and SSFR) after IMRT. No significant changes in the XQS or LSS were noted in 12 patients who received a total parotid mean dose of ≤3,100 cGy at 1, 3 and 6 months post-IMRT relative to the baseline values. However, for the 22 patients who received >3,100 cGy, significant increases in the XQS and LSS were observed. The USFR and SSFR from the parotid glands in 7 patients who received ≤2,750 cGy were significantly preserved at up to 6 months after IMRT. However, the USFR and SSFR in 27 patients who were treated with >2,750 cGy were significantly lower than the baseline values at all times after IMRT.

Conclusion

We suggest that the total parotid mean dose should be limited to ≤2,750 cGy to preserve the USFR and SSFR and so improve the subsequent quality of life.

Citations

Citations to this article as recorded by

Evaluation of the Effect of Photobiomodulation on Radiation-Induced Xerostomia in Head and Neck Cancer Patients: A Randomized Clinical Trial
Pegah Mosannen Mozaffari, Zahra Delavarian, Reza Fekrazad, Azar Fani Pakdel, Mahdokht Rashed Mohassel, Mohammad Taghi Shakeri, Ala Ghazi
Journal of Lasers in Medical Sciences.2024; 15: e4. CrossRef
Salivary microbiome changes distinguish response to chemoradiotherapy in patients with oral cancer
Marcell Costa de Medeiros, Stephanie The, Emily Bellile, Nickole Russo, Ligia Schmitd, Erika Danella, Priyanka Singh, Rajat Banerjee, Christine Bassis, George R. Murphy, Maureen A. Sartor, Isabelle Lombaert, Thomas M. Schmidt, Avi Eisbruch, Carol Anne Mur
Microbiome.2023;[Epub] CrossRef
Translation and cross-cultural adaption of the Chinese version of the Vanderbilt Head and Neck Symptom Survey version 2.0: a tool for oral symptom assessment in head and neck cancer patients
Min Jin, Li Sun, Rui Meng, Wenjing Wang, Rui Sun, Jing Huang, You Qin, Bian Wu, Qian Ding, Gang Peng, Tao Zhang, Kunyu Yang
Health and Quality of Life Outcomes.2021;[Epub] CrossRef
Study of dosimetry and clinical factors for assessment of xerostomia in head and neck squamous cell carcinoma treated by intensity-modulated radiotherapy: A prospective study
Vrinda Singla, Vipul Nautiyal, Meenu Gupta, Viney Kumar, Shivani Mehra, Mushtaq Ahmad
Journal of Carcinogenesis.2021; 20(1): 14. CrossRef
Radiotherapy-related quality of life in patients with head and neck cancers: a meta-analysis
Xiuhong Ge, Zhengluan Liao, Jianhua Yuan, Dewang Mao, Yumei Li, Enyan Yu, Xunheng Wang, Zhongxiang Ding
Supportive Care in Cancer.2020; 28(6): 2701. CrossRef
Xerostomia, salivary characteristics and gland volumes following intensity‐modulated radiotherapy for nasopharyngeal carcinoma: a two‐year follow up
CPC Sim, YL Soong, EPP Pang, C Lim, GD Walker, DJ Manton, EC Reynolds, JTS Wee
Australian Dental Journal.2018; 63(2): 217. CrossRef
Radiotherapy changes salivary properties and impacts quality of life of children with Hodgkin disease
L. Marangoni-Lopes, L.P. Rodrigues, R.H. Mendonça, M. Nobre-dos Santos
Archives of Oral Biology.2016; 72: 99. CrossRef
Is linac-based volumetric modulated arc therapy better than helical tomotherapy in the radiotherapy of nasopharyngeal carcinoma?
Vincent W. C. Wu, Bing-kin Choi, Ho-nam Chan, Ruby Lam, Yu-king Wong, Alan W. L. Mui, George Chiu
Journal of Radiation Oncology.2015; 4(1): 29. CrossRef
Preventing and Therapeutic Effect of Propolis in Radiotherapy Induced Mucositis of Head and Neck Cancers: A Triple-Blind, Randomized, Placebo-Controlled Trial
Abbas Javadzadeh Bolouri, Atessa Pakfetrat, Arghavan Tonkaboni, Seyed Amir Aledavood, Mohsen Fathi Najafi, Zahra Delavarian, Mohammad Taghi Shakeri, Azade Mohtashami
Iranian Journal of Cancer Prevention.2015;[Epub] CrossRef
Evaluation of an automated knowledge based treatment planning system for head and neck
Jerome Krayenbuehl, Ian Norton, Gabriela Studer, Matthias Guckenberger
Radiation Oncology.2015;[Epub] CrossRef
Translation and validation of the Chinese version of the quality of life radiation therapy instrument and the head & neck module (QOL-RTI/H&N)
Xin-lin Chen, Zhen-wen Qiu, Mo-fa Gu, Yong Su, Li-zhi Liu, Yan Liu, Chuan-wei Mo, Qian Xu, Juan Sun, Dong-hai Li
Health and Quality of Life Outcomes.2014;[Epub] CrossRef
Correlation of Parotid Gland Function in Head and Neck Cancer Patients treated with Intensity-modulated Radiotherapy
Sonal Vahanwala, Sukhjinder Kaur Khosa, Sandeep S Pagare
International Journal of Head and Neck Surgery.2012; 3(1): 1. CrossRef
Effects of Intensity-modulated Radiotherapy on Human Oral Microflora
Zi-Yang SHAO, Zi-Sheng TANG, Chao YAN, Yun-Tao JIANG, Rui MA, Zheng LIU, Zheng-Wei HUANG
Journal of Radiation Research.2011; 52(6): 834. CrossRef

15,071 View
105 Download
13 Crossref

The Effect of Adjuvant Chemotherapy with Cyclophosphamide , Methotrexate , and 5 - Fluorouracil ( CMF ) following Radical Mastectomy in Fem: Eun Hee Koh, Joo Hang Kim, Byung Soo Kim, Cheong Soo Park, Jin Sik Min, Kyung Shik Lee, Choon Kyu Kim, Kwan Ho Cho, Chang Ok Suh, Gwi Eon Kim; J Korean Cancer Assoc. 1985;17(1):16-25.

Abstract PDF: The forty-one female patients of breast cancer were treated with adjuvant chemotherapy following radical mastectomy were retrospectively analyaed with compared to aixty patienr.s treated with postoperative radiotherapy. The chemotherapy consisted of 12 monthly cycles of cyclophosphamide, methotrexate and 5-fluorouracil. After 45 months of study, the comparative relapse-free survival rate at three years waa significantly higher in chemotherapy group(chemotherapy group 78.0%, radiocherapy group 41. 1%: P(0.01). At three years 92.3% of patients given chemotherapy and 72, 5% of radio- therapy group remained alive. This difference was not significant. The patients with four or more positive axillary nodes had a higher per cent of relapses than those with fewer nodes. Three-year relapse-free suvival rate of chemotherapy group was aignificantly improved compared to radiotherapy group irrespective of the number of the axillary lymph nodes affected. The three-year relapse-free survival rates in hoth premenopausal women(chemotherapy group 76.5%, radiotherapy group 46.3%) and postmenopausal group(chemotherapy group 73.3%, radiotherapy group 42.0%) were increased in chemotherapy group than radiotherapy group, but statistically significant difference couldn't obtain in postmenopausal women. Five of 41 patients(12. 2i.) in chemotherapy group and 23 of 60 Patients(38.3%) in radio- therapy group had experienced reeurrence. The sites of the initial recurrence of all six patients in chemotherapy group were local-regional area, while 21 of 23 patients in radiothe- rapy group had distant metastases. These results showed postoperative adjuvant radiotherapy alone couldn't prevent distant metastasis at all. The side effects and hematologic toxicities attributable to chemotherapy were moderate and acceptable. Above short-term follow up result represented the encouragement for postoperative adju- vant chemotherapy in female breast cancer, but this study would continue to prove a real decrease rather than postoponement of relapse.

2,772 View
17 Download

Effecacy of Induction chomotherapy in Squamous Cell Carcinoma of the Head and Neck: Joo Hang Kim, Byung Soo Kim, Eun Hee Koh, Yi Hyeong Lee, Gwi Eon Kim, Chang Ok Suh, Won Yong Oh, Kwan Ho Cho, Jin Sil Seong, Won Pyo Hong, Myung Hyun Chung, Won Sang Lee, Cheong Soo Park, Choong Koo; J Korean Cancer Assoc. 1985;17(1):28-34.

Abstract PDF: A clinical study was carried out to investigate the effectiveness and feasjbility of one course of induction chemotherapy with cis-platinum, vincriatine, and bleomycin in 40 patients with squamous cell carcinoma of the head and neck. Twenty three patients(57.5%) had an objective responses; there were 1 complete response (2.5%) and 22 partial responses(55.0%). Responses to chemotherapy was not significantly influenced by disease stage and there were insufficient numbers for a site-by-site comparison. Drug toxicity was tolerable with no life threatening side effects and no added risks to surgery or radiotherapy were encountered. We concluded the effectiveness and feasibility of induction chemotherapy were estabilished.

3,051 View
13 Download

Result of Definitive Irradiation for Regional Stage 4 Carcinoma of the Nasopharynx : An Analysis of the Patterns of Failure: Kwan Ho Cho, Soo Kon Kim, Kyung Ran Park, Mi Son Chun, Chang Ok Suh, Gwi Eon Kim, John J. K. Loh, Joo Hang Kim, Byung Soo Kim, Eun Hee Koh; J Korean Cancer Assoc. 1985;17(2):229-237.

Abstract PDF: Between January 1, 1971 and December 31, 1983, sixty three patients received radiotherapy for advanced (Stage IV) carcinoma of the nasopharynx confined to the head and neck at Yonsei University College of Medicine, Yonsei Cancer Center. Fifty seven of those 63 patients received at least 6,000 cGy. The 5 and 10 year actuarial survival rates were 21.8 and 13.1% and those median survival was 24 months. The actuarial survivals (median survival months) for Group 1 (16 who had sufficiently advanced primary tumor to qualify for Stage IV : T4 N0orl), Group 2 (34 who had sufficiently advanced adenopathy to qualify for Stage IV: T1-3N2or 3) and Group 3 ( 13 who had advanced both of primary and adenopathy: T4 N 2 or 3) were 9.7(19), 32.9(44) and 0%(9) respectively. The survival of the patients in Group 2 was better than that of those in either Group 1(p<0.005) or Group 3(p<0.001). Local persistence or recurrence of tumor in the nasopharynx was the primary cause of failure and occurred in 39.1%(18/46) of evaluable patents. Distant metastases was the next and occurred in 28.3%(13/46). There was a definite correlation between recurrence at primary site and T-stage; 61.5%(8/13) of evaluable Group 1 and 61.9%(13/21) of T 4 patients (Group 3 included) had local failure. Similary, failure in the neck (regional failure) correlated with N-stage, being 24%(9/25) for evaluable Group 2. The incidence of distant failure had no correlation with T-stage but correlated with N-stage; 40%(10/25) of Group 2 developed distant metastases. Treatment failure occured in 95%(36/38) of the patients by 2 years after therapy.

2,730 View
14 Download

Radiotherapy Results of Testicular Pure Seminoma: Soo Kon Kim, Kwan Ho Cho, Mi Soo Hwang, Gwi Eon Kim, Chang Yun Park; J Korean Cancer Assoc. 1986;18(1):41-49.

Abstract PDF: Between 1971 and 1983, 26 Patients with testicular pure seminoma treated at the Yonsei Cancer Center with radiotherapy are analyzed. The stage distribution was: stage I 46%(12/26), stage B 42%(11/26), and stage III 12% (3/26). Tumor histological subtypes were typical seminoma in 8 patients, anaplastic seminoma in 4 patients, and unknown subtypes in 14 patients. Three-year actuarial disease free survival rate was: overall 76%, stage I 91%', stage II 80%, stage III 0%, Treatment failure were analyzed to determine their apparent causes and the implication of such failures to the future management of the testicular pure seminoma.

2,120 View
17 Download

First
Prev
Page of 1
Next
Last

Search